Full Press Release Details
Bio Announces Launch of Proposed Public Offering
PENNSYLVANIA, October 30, 2023 /BUSINESS WIRE/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis"), a late-stage
clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer's Disease
and Parkinson's Disease, today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares
of its common stock and (ii) an accompanying warrant to purchase shares of common stock. The shares of common stock and the accompanying
warrant will be issued separately but can only be purchased together in the offering. All of the shares of common stock and the accompanying
warrant are being offered by Annovis. The offering is subject to market and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or terms of the offering.
is acting as the sole bookrunner in the offering.
to use the net proceeds from this offering, together with its existing cash, for expenses primarily related to general corporate purposes,
including to fund the clinical development of Annovis' lead drug candidate, buntanetap, including the conduct of Annovis'
on-going and planned clinical trials, potential future commercialization efforts, and future regulatory activities including preparation
of regulatory filings; and for additional early-stage research and development activities; and other general corporate purposes.
and the accompanying warrant are being offered by Annovis pursuant to an effective shelf registration statement on Form S-3 (No. 333-252625)
previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus supplement and accompanying prospectus describing
the terms of the proposed offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering may be obtained from: Canaccord Genuity LLC, Attention: Syndication Department, 99
High Street, Suite 1200, Boston, Massachusetts 02110, or by email at prospectus@cgf.com. Electronic copies of the preliminary prospectus
supplement and accompanying prospectus will also be available on the SEC's website at http://www.sec.gov.
release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or other jurisdiction.
About Annovis Bio, Inc.
Headquartered in Berwyn, Pa., Annovis
Bio, Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's Disease (AD), Parkinson's
Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD
designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company's
goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For information
about the company's clinical trials and patents, visit annovisbio.com.
Forward-Looking Statements
This press release contains "forward-looking"
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking
statements. The Company advises caution in reliance on forward-looking statements. Forward-looking statements include, without limitation,
the Company's plans related to clinical trials. These statements involve known and unknown risks, uncertainties and other factors that
may cause actual results to differ materially from those implied by forward-looking statements, including regarding patient enrollment,
the effectiveness of Buntanetap and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the
efficacy, safety and tolerability of buntanetap. See also additional risk factors set forth in the Company's periodic filings with the
SEC, including, but not limited to, those risks and uncertainties listed in the section entitled "Risk Factors," in the Company's
Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC. All forward-looking statements in this press
release are based on information available to the Company as of the date of this filing. The Company expressly disclaims any obligation
to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise, except as required